Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: mact who wrote (84)	11/16/2002 1:11:47 PM
From: tuck	Read Replies (1) \| Respond to of 510

Personally, I think the one put together by the Virginia group -- to which CIPH has more direct commercialization rights (with the Correlogic test, I believe all CIPH could do is supply the chips) -- looks better. Message 17979622 At least, superficially. The patient population is not well described in that one. I agree that recent tweaks in the measurement of various parameters of PSA have gotten pretty good (see various articles in the October issue of Urology). However, all these measurements are expensive, and a test of the sort CIPH and Correlogic are exploring would likely have better cost/benefit as a first line screening tool. Have you looked at the results of the various multiple biomarker studies? Am I all wet in believing that some are ready for prime time? The company has said it would pick the two most promising ones for commercialization. Which would you pick? At the moment, I like early detection of breast cancer (the Johns Hopkins study). It's also a big market, and the cost/benefit is less murky than with prostate cancer screening. Message 17871228 Not sure at this point what else I'd shoot for. Cheers, Tuck